(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report - Wikidata - wikimedia - TriplyDB

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

http://www.wikidata.org/entity/Q26747480

about

Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.Investigation of the halo-artifact in 68Ga-PSMA-11-PET/MRI Multimodality Image Fusion with PSMA PET/CT and High-Intensity Focused Ultrasound Focal Therapy for Primary Diagnosis and Management of Prostate Cancer: A Planned Research Initiative.The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.(68)Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography.Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions.68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.Effect of Time-of-Flight and Regularized Reconstructions on Quantitative Measurements and Qualitative Assessments in Newly Diagnosed Prostate Cancer With 18F-Fluorocholine Dual Time Point PET/MRI.Exploring Metabolism In Vivo Using Endogenous 11C Metabolic Tracers.Clinical Pearls: Etiologies of Superscan Appearance on Fluorine-18-Fludeoxyglucose Positron Emission Tomography-Computed Tomography.68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer.Evaluation of the changing landscape of prostate cancer diagnosis and management from 2005 to 2016.68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions.68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour.PSA-stratified detection rates for [68Ga]THP-PSMA, a novel probe for rapid kit-based 68Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer.Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.Actual impact of 68Ga-PSMA-11 PET/CT on the management of prostate cancer patients with biochemical recurrence.68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning.Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging.Role of Early Dynamic Positron Emission Tomography/Computed Tomography with 68Ga-prostate-specific Membrane Antigen-HBED-CC in Patients with Adenocarcinoma Prostate: Initial Results.Impact of 68Ga-PSMA-PET imaging on target volume definition and guidelines in radiation oncology - a patterns of failure analysis in patients with primary diagnosis of prostate cancer.The impact of a Bayesian penalized-likelihood reconstruction algorithm on delayed-time-point Ga-68-PSMA PET for improved recurrent prostate cancer detection.Can Early Dynamic Positron Emission Tomography/Computed Tomography Obviate the Need for Postdiuresis Image in 68Ga-PSMA-HBED-CC Scan for Evaluation of Prostate Adenocarcinoma?Keeping up with the prostate-specific membrane antigens (PSMAs): an introduction to a new class of positron emission tomography (PET) imaging agents

P2860

Q31145236-ABF582FE-DC34-49D7-8802-038BABA17550 Q38619857-B9B7C4F4-FFAF-4630-95B1-D97C897C818B Q38641232-5179FBE7-2247-4077-BED9-9D0F35A0B00F Q38648799-59E94778-A359-4F69-86D1-6D45816CB59C Q38747415-2040D037-B671-4130-8028-0EEA4A0C9B54 Q38757513-C24B9746-C81B-4925-BEDF-48DA041750D3 Q40188618-EB63D851-FE62-4517-BDDD-6C9CFCB778CA Q46225464-2E5D7DE4-CADB-452A-AA46-5ABC54F1B1A6 Q46423605-134AAC62-B69F-4893-BB69-04A2C3179BF2 Q46851666-22DF5DCC-9D0E-4BE0-9C46-832A47069070 Q47094574-AC803215-32AB-4228-8C4E-77694007CDA2 Q47147617-A57F53E5-BDAE-412A-8CB0-047C777D5C8B Q47153081-C343AA18-B852-4911-B234-8EC2A7A3C13B Q47273452-E0B1B3E4-7D4C-43F2-9A26-7AE80DCFA544 Q48141689-44D71FA9-CD95-4F60-8B59-56638FA53460 Q48189196-E4A8A8B8-91EF-4D70-9961-5AF1DA1DD688 Q48295687-BD6E3B9A-DDD2-47DF-9BD8-E3A5361C8B7C Q48297324-A2FD4626-79A9-4446-A2E9-37A333271BE8 Q48316900-6A16A62A-0249-4954-965C-A5A29330960C Q48568705-D3C3E97B-A141-41E7-83CC-AB6DD52693EF Q50083626-14B915F1-8C13-4076-8D00-AA9349A99CD2 Q51840218-F14F5280-6765-46C5-BAF6-49AE33773548 Q52593000-FC0AEAF6-429D-4CF3-B127-1A541BF354E9 Q52680980-869A6617-166A-419A-A8C8-1C75906CE07E Q55293334-74EDFE89-72A5-4996-9D72-4F798003E0B6 Q55402710-9061C2CF-1963-48C8-AB80-D0B2B6D867DB Q59130960-2C4BFF77-BDB2-4E70-BC98-09D1F7EE4859

P2860

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

http://www.wikidata.org/entity/Q26747480

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

@ast

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

@en

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

@nl

type

label

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

@ast

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

@en

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

@nl

prefLabel

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

@ast

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

@en

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

@nl

P1433

Q26747480-28F962FB-CC6A-4F19-84CD-F337C623B5C5

P1476

Q26747480-B5C5D56B-DEA9-45A9-8EF3-F7E5BF2AD3C8

P2093

Q26747480-3571124A-07E5-4C07-A82E-9D31AA4152A7

Q26747480-693029E5-C832-423E-9EA3-93433A82338D

Q26747480-6F4CA693-85F7-429A-BCEA-DAAFE9EB6CE9

Q26747480-814BE0FB-6B00-4C74-AE1B-51AFE0C7A7DC

P275

Q26747480-233604E2-2981-4B9D-A714-D1D27FEC3E2F

P2860

Q26747480-041B5281-0CCF-4ACD-9730-86E0DF7D51AE

Q26747480-0BE69DD7-E75C-4C6F-9CC6-AA64F41CD3B8

Q26747480-0D3FACE5-1EE7-4F78-A63E-14DC59A12A14

Q26747480-1492BB98-BF22-454D-876F-2E9B6056A68A

Q26747480-18609B7B-3F99-4098-8EC6-4C093EC2B323

Q26747480-1E74500E-DB1D-429E-A410-59D7066CBF13

Q26747480-2657814E-F3CF-41A9-B52D-529EAD400F6C

Q26747480-2924F72D-AE26-435D-9602-B75BAAC90860

Q26747480-32E74926-6821-43B5-BCBB-2C8565130934

Q26747480-3FE31DC6-7718-48B3-9C46-8E1BB91400A7

P2888

Q26747480-2A4D7675-117C-402D-A9CC-492F2E8F3200

P304

Q26747480-C5530A45-C531-46FD-93F1-76F555FCE113

P31

Q26747480-56D1B50C-B315-42B9-A8AA-7F152C1ED135

Q26747480-C94DE992-BDB0-4084-8C5E-05D85D7EAA3E

P3181

Q26747480-43089728-146A-4428-84C1-2799DA9ED35E

P356

Q26747480-2D09BDCF-68C9-4468-AA08-DF2666A2CFFC

P407

Q26747480-FB96736F-EC81-4A60-AF14-EE3383D6359B

P433

Q26747480-B13B887D-6058-4199-9D75-9544D72A2BC1

P478

Q26747480-C8C1C64C-67C4-43E8-A02D-714C37FF59F1

P50

Q26747480-65F7D58F-B5F4-4039-9748-A8B54808F280

Q26747480-BBB805BD-FBF5-43B4-B780-165061655A87

P5008

Q26747480-9994EA71-5078-4C46-B780-2FF09006DCD6

P577

Q26747480-017EFA27-BAA5-4F3C-86B5-8F6E3D1E714C

P6179

Q26747480-E4E52110-3B60-4A01-A1E5-276CDF358899

P698

Q26747480-3CAE3CC8-7AE8-40D1-A54D-87ACBAE443CD

P921

Q26747480-4276DAA3-6BB4-4914-BA2D-44C3A64DFC5F

Q26747480-91074F5E-707D-43A8-9FAD-52EC0EBDB9E0

Q26747480-A1736979-33CB-4432-B11A-82E93FFBA251

Q26747480-BF2325F0-AF8B-4F98-B36D-68CBC1815822

Q26747480-D29AD311-DDA8-470B-ACCD-8C7DF571A35B

Q26747480-F062BF14-036A-4D6B-82B5-65CFDA1F9B2A

P932

Q26747480-790BC1C1-4D32-41E4-B377-D691CBBD3876

P3181

P356

S40644-016-0072-6

P1433

P1476

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report

@en

P2093

Markus Schwaiger

http://www.w3.org/2001/XMLSchema#string

Matthias Eiber

http://www.w3.org/2001/XMLSchema#string

Wieland H Sommer

http://www.w3.org/2001/XMLSchema#string

Wolfgang P Fendler

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Global cancer statistics, 2012

PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2

Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis.

18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.

Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.

Structured reporting: a fusion reactor hungry for fuel.

Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer

Fluorocholine PET/CT in patients with prostate cancer: initial experience.

P2888

s40644-016-0072-6

P304

14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

932019

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S40644-016-0072-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Isabel Rauscher

P5008

P577

2016-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1023676471

http://www.w3.org/2001/XMLSchema#string

P698

27277843

http://www.w3.org/2001/XMLSchema#string

P921

carboxylic acid

prostate cancer

mechanism of action

multimodal imaging

P932

4898465

http://www.w3.org/2001/XMLSchema#string